Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: Comparison of 18F-FDG PET/CT and contrast-enhanced CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 7, 2013, Pages 1014-1024

  Schramm, N ^a   Rominger, A ^a   Schmidt, C ^a   Morelli, J N ^b   Schmid Tannwald, C ^a   Meinel, F G ^a   Reiser, M F ^a   Rist, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Contrast enhanced CT; Paraneoplastic neurological syndrome; PET CT; Tumour detection

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOMEPROL;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BONE METASTASIS; BREAST CANCER; BRONCHUS CANCER; CANCER DIAGNOSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PARANEOPLASTIC NEUROPATHY; PET SCANNER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SOFT TISSUE METASTASIS; THYMUS CANCER; TONSIL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; OBSERVER VARIATION; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84879506270     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2372-4     Document Type: Article

References (32)

1. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-5.
2. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med. 2004;45 Suppl 1:56S-65S.
3. Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanché JP, Confavreux C, et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol. 2000;48:105-8.
4. Bannas P, Weber C, Derlin T, Lambert J, Leypoldt F, Adam G, et al. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol. 2010;20:923-30.
5. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-9.
6. Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008;49:17N-21N 37N.
7. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157-164.
8. Cashman EC, Macmahon PJ, Shelly MJ, Kavanagh EC. Role of positron emission tomography-computed tomography in head and neck cancer. Ann Otol Rhinol Laryngol. 2011;120:593-602.
9. Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings AJR Am J Roentgenol 1998;170:1513-157.
10. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327-40.
11. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543-54.
12. Frings M, Antoch G, Knorn P, Freudenberg L, Bier U, Timmann D, et al. Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol. 2005;252:197-201.
13. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135-40.
14. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138-48.
15. Hadjivassiliou M, Alder SJ, Van Beek EJ, Hanney MB, Lorenz E, Rao DG, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand. 2009;119:186-93.
16. Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:479-82.
17. Kumar A, Regmi SK, Dutta R, Kumar R, Gupta SD, Das P, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med. 2009;23:569-77.
18. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63:282-6.
19. Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol. 2007;62:328-34.
20. Liu RS, Yeh SH, Huang MH, Wang LS, Chu LS, Chang CP, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med. 1995;22:1402-7.
21. Matsuhisa A, Toriihara A, Kubota K, Makino T, Mizusawa H, Shibuya H, et al. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes. Clin Nucl Med. 2012;37:39-43.
22. Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR, et al. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc 2008;83:917-22.
23. Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001;124:2223-31.
24. Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55:713-5.
25. Rosenfeld MR, Dalmau J. Update on paraneoplastic neurologic disorders. Oncologist. 2010;15:603-17.
26. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve. 2000;23:1800-18.
27. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19-e13.
28. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26:4276-81.
29. Tsujikawa T, Tsuchida T, Yoshida Y, Kurokawa T, Kiyono Y, Okazawa H, et al. Role of PET/CT in gynecological tumors based on the revised FIGO staging classification. Clin Nucl Med. 2011;36:e114-8.
30. Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13:682-90.
31. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002;1:294-305.
32. Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127:2331-8.